{
  "docId": "019de070-1001-704a-89ab-d7496f4fd716",
  "docSlug": "51e89351998d2fd4ac099e485858473c",
  "documentTitle": "BioNTech | Results Presentation Deck | 11 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 11,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "other",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de070-1001-704a-89ab-d7496f4fd716/8",
  "deckHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716",
  "deckJsonHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716.json",
  "deckAnchorHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "list",
      "text": "Joint establishment of pandemic supply capacities at many network sites\nBioNTech: At Idar-Oberstein and Mainz facilities in Germany\nPfizer: At least at three U.S. sites (Massachusetts, Michigan, Missouri) and at Puurs facility (Belgium)\nBioNTech and Pfizer working closely together (joint teams) on scale-up, supply chain and network planning",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c773d69-9bca-4767-937a-e5a87a8630e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.24
      },
      "kind": "list",
      "text": "BioNTech to manufacture all drug substance for clinical supply at its GMP manufacturing facilities in Idar-Oberstein and Mainz (both in Germany, partially 24/7 manufacturing)\nDrug product supply initially supported by BioNTech's formulation partner Polymun, with Pfizer and BioNTech ramping up own capacity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d32c0a1-55e9-4f0e-979c-3e802a7876d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT162 Manufacturing Update",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3a451fc-f666-4398-bd1d-c0cd8d2b60fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.04,
        "y": 0.48
      },
      "kind": "title",
      "text": "Global pandemic and commercial supply capacities",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "427cdf22-c646-48f0-90f2-b469a879ebc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "title",
      "text": "Clinical supply",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b047e3b8-f2e3-465f-8c74-ff00d8869200",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "a1e10f88-6e5d-473c-a25a-cabcc03d02ec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Slides 4 and 10 provide key takeaways on the COVID-19 program and building a next-generation immunotherapy company.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}